Nifty
Sensex
:
:
11404.70
37956.05
50.45 (0.44%)
147.14 (0.39%)

Pharmaceuticals & Drugs

Rating :
48/99

BSE: 500257 | NSE: LUPIN

734.90
5.85 (0.80%)
26-Mar-2019 | 1:49PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  733.00
  •  738.65
  •  731.15
  •  729.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  968589
  •  7118.16
  •  986.10
  •  723.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 32,990.55
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 38,725.32
  • 0.69%
  • 2.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.98%
  • 1.13%
  • 11.34%
  • FII
  • DII
  • Others
  • 0.39%
  • 10.95%
  • 29.21%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.12
  • 6.97
  • 3.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.59
  • 0.95
  • -3.11

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -6.87
  • -33.01
  • -52.11

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.61
  • 26.48
  • 23.47

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.73
  • 5.61
  • 3.97

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.24
  • 16.57
  • 14.48

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
4,504.87
3,975.62
13.31%
3,951.06
3,951.96
-0.02%
3,855.93
3,869.58
-0.35%
4,033.83
4,253.30
-5.16%
Expenses
3,752.33
3,287.28
14.15%
3,401.42
3,098.91
9.76%
3,328.96
3,101.21
7.34%
3,325.08
3,471.93
-4.23%
EBITDA
752.54
688.34
9.33%
549.64
853.05
-35.57%
526.97
768.37
-31.42%
708.75
781.37
-9.29%
EBIDTM
16.70%
17.31%
13.91%
21.59%
13.67%
19.86%
17.57%
18.37%
Other Income
43.42
28.42
52.78%
230.68
74.04
211.56%
184.20
31.97
476.17%
144.92
45.34
219.63%
Interest
79.77
54.00
47.72%
73.82
47.92
54.05%
68.72
43.90
56.54%
58.53
40.62
44.09%
Depreciation
279.76
280.35
-0.21%
265.49
272.18
-2.46%
258.98
260.51
-0.59%
272.83
267.42
2.02%
PBT
94.21
382.41
-75.36%
441.01
606.99
-27.34%
383.47
495.93
-22.68%
-942.04
518.67
-
Tax
247.80
160.77
54.13%
172.91
154.06
12.24%
181.14
136.81
32.40%
-163.18
136.68
-
PAT
-153.59
221.64
-
268.10
452.93
-40.81%
202.33
359.12
-43.66%
-778.86
381.99
-
PATM
-3.41%
5.58%
6.79%
11.46%
5.25%
9.28%
-19.31%
8.98%
EPS
-3.35
4.91
-
5.88
10.07
-41.61%
4.48
7.93
-43.51%
-17.33
8.42
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
16,345.69
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
4,870.79
3,866.64
Net Sales Growth
1.84%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
19.47%
25.97%
 
Cost Of Goods Sold
5,800.52
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
1,821.29
1,604.09
Gross Profit
10,545.17
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
3,049.50
2,262.55
GP Margin
64.51%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
62.61%
58.51%
Total Expenditure
13,807.79
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
3,886.90
3,127.36
Power & Fuel Cost
-
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
154.66
139.11
% Of Sales
-
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
3.18%
3.60%
Employee Cost
-
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
549.96
474.16
% Of Sales
-
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
11.29%
12.26%
Manufacturing Exp.
-
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
500.14
261.34
% Of Sales
-
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
10.27%
6.76%
General & Admin Exp.
-
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
292.37
192.75
% Of Sales
-
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
6.00%
4.98%
Selling & Distn. Exp.
-
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
446.97
354.48
% Of Sales
-
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
9.18%
9.17%
Miscellaneous Exp.
-
166.20
283.61
204.82
271.21
283.96
184.88
162.80
130.76
121.51
354.48
% Of Sales
-
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
2.49%
2.62%
EBITDA
2,537.90
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
983.89
739.28
EBITDA Margin
15.53%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
20.20%
19.12%
Other Income
603.22
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
14.20
4.61
Interest
280.84
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
38.49
49.86
Depreciation
1,077.06
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
123.91
87.99
PBT
-23.35
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
606.04
Tax
438.67
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
136.02
98.30
Tax Rate
-1,878.67%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
16.28%
16.22%
PAT
-462.02
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
688.51
504.88
PAT before Minority Interest
-470.08
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
699.67
507.74
Minority Interest
-8.06
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
-11.16
-2.86
PAT Margin
-2.83%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
14.14%
13.06%
PAT Growth
-132.64%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
25.57%
36.37%
 
Unadjusted EPS
-10.32
5.56
56.69
50.25
53.54
40.99
29.39
19.43
19.36
15.84
60.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
2,567.83
1,424.82
Share Capital
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
88.94
82.82
Total Reserves
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
2,478.35
1,341.93
Non-Current Liabilities
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
1,283.35
1,339.71
Secured Loans
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
872.24
756.92
Unsecured Loans
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
267.61
466.35
Long Term Provisions
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
0.00
0.00
Current Liabilities
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
1,189.25
1,216.19
Trade Payables
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
883.52
710.25
Other Current Liabilities
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
82.82
323.23
Short Term Borrowings
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
0.00
0.00
Short Term Provisions
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
222.91
182.71
Total Liabilities
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
3,994.97
Net Block
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
1,906.17
1,518.57
Gross Block
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
2,613.39
2,137.40
Accumulated Depreciation
2,459.58
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
707.22
618.83
Non Current Assets
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
2,290.47
1,764.10
Capital Work in Progress
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
348.80
222.62
Non Current Investment
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
26.43
21.56
Long Term Loans & Adv.
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
0.00
0.00
Other Non Current Assets
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
0.00
0.00
Current Assets
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
2,775.45
2,230.87
Current Investments
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
0.00
0.00
Inventories
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
971.49
957.16
Sundry Debtors
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
1,126.57
917.97
Cash & Bank
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
201.53
77.77
Other Current Assets
1,711.95
533.43
479.44
240.07
532.99
572.33
427.17
628.48
475.86
277.97
Short Term Loans & Adv.
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
475.86
277.97
Net Current Assets
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
1,586.20
1,014.68
Total Assets
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
3,994.97

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
676.41
469.54
PBT
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
606.04
Adjustment
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
144.33
144.21
Changes in Working Capital
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
-136.62
-173.89
Cash after chg. in Working capital
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
843.40
576.36
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
-166.99
-106.82
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,407.27
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
-680.17
-509.62
Net Fixed Assets
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
-309.75
-223.23
Net Investments
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
-250.20
-181.38
Others
-1,564.03
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
-120.22
-105.01
Cash from Financing Activity
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
136.13
-167.15
Net Cash Inflow / Outflow
-1,148.18
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
132.37
-207.23
Opening Cash & Equivalents
2,799.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
68.08
270.66
Closing Cash & Equivalent
1,651.29
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88
197.99
68.08

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
57.73
34.41
ROA
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
15.44%
13.83%
ROE
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
35.05%
37.55%
ROCE
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
27.51%
25.57%
Fixed Asset Turnover
1.20
1.62
1.80
2.15
2.28
2.19
1.99
2.10
2.06
2.05
Receivable days
109.70
92.39
92.24
72.65
74.67
74.61
77.76
74.26
76.18
77.48
Inventory Days
84.35
72.15
73.96
65.73
65.48
69.24
75.12
67.69
71.86
81.42
Payable days
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
64.47
62.70
Cash Conversion Cycle
125.48
104.91
103.00
73.94
76.37
80.10
88.76
80.49
83.57
96.21
Total Debt/Equity
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
0.44
0.86
Interest Cover
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84
22.71
13.15

News Update:


  • Lupin, YL Biologics receive PMDA approval for Etanercept biosimilar in Japan
    26th Mar 2019, 11:45 AM

    The approval to treat moderate to severe Rheumatoid Arthritis and Juvenile Idiopathic Arthritis was received on March 26, 2019

    Read More
  • Lupin receives USFDA’s approval for Sildenafil Tablets
    25th Mar 2019, 11:57 AM

    Sildenafil Tablets USP had an annual sales of approximately $611 million in the US

    Read More
  • Lupin launches Levothyroxine Sodium Tablets
    22nd Mar 2019, 12:28 PM

    Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc’s Synthroid Tablets

    Read More
  • USFDA classifies Lupin's Somerset facility as ‘Official Action Indicated’
    18th Mar 2019, 10:26 AM

    Official Action Indicated means approvals of pending applications or supplements from this site maybe withheld

    Read More
  • Lupin gets USFDA’s approval for Atorvastatin Calcium Tablets
    8th Mar 2019, 09:05 AM

    Atorvastatin is also prescribed to lower the risk for heart attack, stroke in patients with cardiovascular diseases

    Read More
  • Lupin receives USFDA approval for Imatinib Mesylate Tablets
    5th Mar 2019, 14:11 PM

    Imatinib Mesylate Tablets, 100 mg and 400 mg had annual sales of approximately $655 mn in the US

    Read More
  • Lupin gets USFDA’s approval for Azacitidine for Injection, 100 mg Single-Dose Vial
    28th Feb 2019, 15:27 PM

    With this approval, Lupin strengthens its complex generics portfolio in Injectables

    Read More
  • Lupin launches Generic Ranolazine ER Tablets in US
    28th Feb 2019, 10:50 AM

    Ranolazine is indicated for the treatment of chronic angina

    Read More
  • Lupin launches generic Minocycline Hydrochloride ER Tablets
    26th Feb 2019, 14:31 PM

    It is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older

    Read More
  • Lupin gets USFDA’s approval for Methylprednisolone Tablets
    25th Feb 2019, 16:15 PM

    Methylprednisolone Tablets had annual sales of approximately $114.3 million in the US

    Read More
  • Lupin recalls 43,860 bottles of ophthalmic solution in US
    22nd Feb 2019, 10:38 AM

    USFDA has classified it as a class-III recall, which is initiated in a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences

    Read More
  • Lupin launches Clobazam Oral Suspension
    15th Feb 2019, 15:46 PM

    Clobazam Oral Suspension, 2.5mg/mL had annual sales of $253 million in the US

    Read More
  • Lupin launches Tadalafil Tablets
    12th Feb 2019, 14:49 PM

    The company’s Tadalafil Tablets USP 20mg is the generic equivalent of Eli Lilly's Adcirca Tablets 20mg

    Read More
  • USFDA completes inspection of Lupin’s Goa facility
    11th Feb 2019, 09:52 AM

    The observations are procedural in nature and the company is confident of addressing them satisfactorily

    Read More
  • Lupin gets approval from USFDA for Tadalafil tablets
    7th Feb 2019, 10:08 AM

    The company's Tadalafil Tablets USP, 20 mg is the generic version of Eli Lilly and Company's Adcirca Tablets, 20 mg

    Read More
  • Lupin reports consolidated net loss of Rs 152 crore in Q3
    6th Feb 2019, 14:57 PM

    Total consolidated income of the company increased by 13.59% at Rs 4548.29 crore for Q3FY19

    Read More
  • Lupin - Quarterly Results
    6th Feb 2019, 14:28 PM

    Read More
  • Lupin launches Clomipramine Hydrochloride Capsules
    5th Feb 2019, 15:38 PM

    It is indicated for the treatment of obsessions and compulsions in patients with OCD

    Read More
  • Lupin recalling over 24000 bottles of Fluocinolone Acetonide from US
    4th Feb 2019, 09:29 AM

    The reason for the recall is failed impurities and degradation specifications

    Read More
  • Lupin launches orphan drug NaMuscla in Germany, UK
    1st Feb 2019, 16:24 PM

    The product will be commercialized in Germany by Hormosan Pharma GmbH, a full subsidiary of Lupin, and in the UK by Lupin Healthcare (UK)

    Read More
  • USFDA completes inspection at Lupin’s Indore facility
    28th Jan 2019, 08:59 AM

    The inspection was carried out between January 14 and January 25, 2019

    Read More
  • Lupin gets USFDA’s approval for Levothyroxine Sodium Tablets
    21st Jan 2019, 15:11 PM

    Levothyroxine Sodium Tablets had annual sales of approximately $2519.6 million in the US

    Read More
  • Lupin recalling anti-bacterial drug Ceftriaxone from US
    21st Jan 2019, 10:06 AM

    Lupin Pharmaceuticals is also recalling 2,87,784 bottles of Cefdinir for Oral Suspension, used to treat bacterial infections for CGMP

    Read More
  • LupinLife's Corcal Bone & Beauty inks pact with Lakme Fashion Week
    18th Jan 2019, 15:30 PM

    The hunt for Corcal beautifully strong women will begin from January 18

    Read More
  • Lupin developing new drugs to treat cancer, metabolic disorders
    14th Jan 2019, 09:34 AM

    The NDDD is focused and committed on developing a pipeline of highly differentiated and innovative new chemical entities

    Read More
  • Lupin recalls over 23,000 bottles of antibiotic drug in US
    9th Jan 2019, 14:48 PM

    The company is recalling the lot due to below specification results for assay

    Read More
  • Lupin gets nod from EC for Orphan Drug NaMuscla
    8th Jan 2019, 11:10 AM

    The company has partnering discussions ongoing for commercialization of NaMuscla in European territories outside Germany and the UK

    Read More
  • Lupin gets USFDA’s approval for Lurasidone Hydrochloride Tablets
    7th Jan 2019, 14:30 PM

    Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg had annual sales of approximately $3217.3 million in the US

    Read More
  • Lupin gets USFDA’s nod for Clobazam Oral Suspension
    31st Dec 2018, 16:08 PM

    Clobazam Oral Suspension, 2.5 mg/mL had annual sales of approximately $260.2 million in the US

    Read More
  • Lupin, AbbVie enters into partnership to develop and commercialize Novel Oncology Drug
    24th Dec 2018, 10:09 AM

    AbbVie gains exclusive global rights to develop and commercialize Lupin's MALT1 inhibitors

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.